Kartzinel R, TEYCHENNE P, Gillespie M M, Perlow M, Gielen A C, Sadowsky D A, Calne D B
Lancet. 1976 Aug 7;2(7980):272-5. doi: 10.1016/s0140-6736(76)90728-5.
Bromocriptine, a dopamine receptor agonist, was administered to 20 patients with idiopathic parkinsonism taking levodopa (L-dopa) or "Sinemet" (levodopa combined with carbidopa in a 10/1 ratio) at optimum doses. In a double-blind randomised cross-over study lasting 6 months, the addition of bromocriptine (mean daily dose 79 mg) led to a significant (P less than 0.01) 74% reduction in the dose of sinemet and levodopa. "Total disability score" showed a significant (P less than 0.01) improvement at both low and high doses of bromocriptine. Tremor improved 50% (P less than 0.01), with significant improvements in gait, posture, writing, balance, rigidity, finger dexterity, and drooling. Adverse reactions were similar to those observed with sinemet and levodopa. Although both the cause and the cure of idiopathic parkinsonism remain elusive, bromocriptine appears to represent a therapeutic advance.
对20名服用左旋多巴（L-多巴）或“息宁”（左旋多巴与卡比多巴按10/1比例混合）且剂量已达最佳的特发性帕金森病患者给予多巴胺受体激动剂溴隐亭。在一项为期6个月的双盲随机交叉研究中，加用溴隐亭（平均日剂量79毫克）使息宁和左旋多巴的剂量显著降低了74%（P<0.01）。“总残疾评分”在低剂量和高剂量溴隐亭治疗时均有显著改善（P<0.01）。震颤改善了50%（P<0.01），步态、姿势、书写、平衡、僵硬、手指灵活性及流涎等方面也有显著改善。不良反应与服用息宁和左旋多巴时观察到的相似。尽管特发性帕金森病的病因和治疗方法仍不明确，但溴隐亭似乎代表了一种治疗进展。
